SCHEMBL16729280

SCHEMBL16729280

Cc1cc2cc(CNC(=O)OC(C)(C)C)ccc2[nH]1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.67
MAPT P10636 7/20 0.67
KDM4E B2RXH2 1/20 0.67
HTT P42858 2/20 0.59
ALOX15 P16050 1/20 0.59
MEN1 O00255 7/20 0.58
KMT2A Q03164 7/20 0.58
SMN1; SMN2 Q16637 5/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
GAA P10253 3/20 0.58
POLB P06746 3/20 0.58
LMNA P02545 2/20 0.57
PABPC1 P11940 1/20 0.57
PKM P14618 2/20 0.57
HPGD P15428 3/20 0.56
USP2 O75604 1/20 0.56
HSP90AA1 P07900 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29377817 1.00 ALDH1A1 (0.67) ALDH1A1MAPTKDM4EHTTALOX15
SCHEMBL1616470 0.84 HPN (0.52) ALDH1A1MAPTKDM4EHTTALOX15
SCHEMBL16720727 0.82 MAPT (0.81) ALDH1A1MAPTKDM4EHTTALOX15
SCHEMBL29792562 0.81 L3MBTL1 (0.49) ALDH1A1MAPTKDM4E
SCHEMBL7214903 0.81 L3MBTL1 (0.49) ALDH1A1MAPTKDM4E
SCHEMBL10209975 0.79 L3MBTL1 (0.47) ALDH1A1MAPTKDM4EALOX15MEN1
SCHEMBL10165007 0.79 MAPK1 (0.62) MEN1KMT2A
SCHEMBL23279829 0.78 CACNA1H (0.43) ALDH1A1MAPTKDM4EHTTALOX15
SCHEMBL16756055 0.77 MAOB (0.58) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3180689 0.77 L3MBTL1 (0.61) MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242557-A9 PROTEASOME ACTIVITY ENHANCING COMPOUNDS Kineta, Inc. 2023-08-03 US disclosed
US-20230242557-A9 PROTEASOME ACTIVITY ENHANCING COMPOUNDS Kineta, Inc. 2023-08-03 US disclosed
US-11242361-B2 Proteasome activity enhancing compounds PROTEOSTASIS THERAPEUTICS, INC. (US) 2022-02-08 US disclosed
US-20200308198-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PROTEOSTASIS THERAPEUTICS, INC. 2020-10-01 US disclosed
US-9850262-B2 Proteasome activity enhancing compounds PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-12-26 US disclosed
US-9850262-B2 Proteasome activity enhancing compounds PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-12-26 US disclosed
US-20160333031-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PROTEOSTASIS THERAPEUTICS, INC. 2016-11-17 US disclosed
US-20160333031-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PROTEOSTASIS THERAPEUTICS, INC. 2016-11-17 US disclosed
WO-2015073528-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333031-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSMB1, PSMC1 ALDH1A1 3439/4885MAPT 943/4885KDM4E 1916/4885
US-20230242557-A9 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSMB1, PSMC1 ALDH1A1 3439/4885MAPT 943/4885KDM4E 1916/4885
US-11242361-B2 Proteasome activity enhancing compounds PSMG3, PSMB1, PSMC1 ALDH1A1 3439/4885MAPT 943/4885KDM4E 1916/4885
US-20200308198-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSMB1, PSMC1 ALDH1A1 3439/4885MAPT 943/4885KDM4E 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.